Jennifer L. Lund

University of North Carolina at Chapel Hill
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Background: Adherence and persistence studies face several methodologic difficulties, including short-term mortality. We compared approaches to quantify adherence and persistence to first line (1L) oral targeted therapy (TT) in patients diagnosed with metastatic renal cell carcinoma (mRCC). Methods: Patients with mRCC ages 66 years or more who initiated TTs within 4 months of diagnosis were identified in the Surveillance, Epidemiology, and End Results Medicare-linked database (2007–2015). Adherence [proportion of days covered (PDC) >80%] was calculated using (i) PDC with a fixed 6-month denominator including then excluding patients who died within the 6 months and (ii) PDC with a denominator measuring time on treatment. Risk of nonpersistence was obtained by censoring death or treating death as a competing risk using cumulative incidence functions. Results: Among 485 patients with mRCC initiating a 1L oral TT (sunitinib, 64%; pazopanib, 25%; other, 11%), 40% died within 6 months. Adherence was higher after restricting to patients who survived (60%) compared with including those patients and assigning zero days covered after death (47%). Risk of nonpersistence was higher when censoring patients at death, 0.91 [95% confidence interval (CI), 0.88–0.94], compared with treating death as a competing risk, 0.75 (95% CI, 0.71–0.79). Conclusions: Different approaches to handling death resulted in different adherence and persistence estimates in the metastatic setting. Future studies should explicitly report the proportion of patient deaths over time and explore appropriate methods to account for death as competing risk. Impact: Use of several approaches can provide a more comprehensive picture of medication-taking behavior in the metastatic setting where death is a major competing risk.

Year:

2025

Background: Endometrial cancer and its treatment may impact urinary system function, but few large-scale studies have examined urinary diagnoses among endometrial cancer survivors. We investigated the risk of several urinary outcomes among older women with endometrial cancer compared with similar women without a cancer history. Methods: Women aged 66+ years with an endometrial cancer diagnosis during 2004–2017 ( N = 44,386) and women without a cancer history ( N = 221,219) matched 1:5 on exact age, race/ethnicity, and state were identified in the Surveillance, Epidemiology, and End Results-Medicare linked data. ICD-9 and -10 diagnosis codes were used to define urinary outcomes in the Medicare claims. HRs for urinary outcomes were estimated using multivariable Cox proportional hazards regression models. Results: Relative to women without cancer, endometrial cancer survivors were at an increased risk of several urinary system diagnoses, including lower urinary tract infection [HR, 2.36; 95% confidence interval (CI), 2.32–2.40], urinary calculus (HR, 2.22; 95% CI, 2.13–2.31), renal failure (HR, 2.28; 95% CI, 2.23–2.33), and chronic kidney disease (HR, 1.85; 95% CI, 1.81–1.90). Similar associations were observed in sensitivity analyses limited to 1+ and 5+ years after endometrial cancer diagnosis. Black race, higher comorbidity index, higher stage or grade cancer, non-endometrioid histology, and treatment with chemotherapy and/or radiation were often significant predictors of urinary outcomes among endometrial cancer survivors. Conclusions: Our results suggest that, among older women, the risk of urinary outcomes is elevated after endometrial cancer. Impact: Monitoring for urinary diseases may be a critical part of long-term survivorship care for older women with an endometrial cancer history.

Year:

2025

Background: Studies evaluating the effects of cancer treatments are prone to immortal time bias that, if unaddressed, can lead to treatments appearing more beneficial than they are. Methods: To demonstrate the impact of immortal time bias, we compared results across several analytic approaches (dichotomous exposure, dichotomous exposure excluding immortal time, time-varying exposure, landmark analysis, clone-censor-weight method), using surgical resection among women with metastatic breast cancer as an example. All adult women diagnosed with incident metastatic breast cancer from 2013–2016 in the National Cancer Database were included. To quantify immortal time bias, we also conducted a simulation study where the “true” relationship between surgical resection and mortality was known. Results: 24,329 women (median age 61, IQR 51–71) were included, and 24% underwent surgical resection. The largest association between resection and mortality was observed when using a dichotomized exposure [HR, 0.54; 95% confidence interval (CI), 0.51–0.57], followed by dichotomous with exclusion of immortal time (HR, 0.62; 95% CI, 0.59–0.65). Results from the time-varying exposure, landmark, and clone-censor-weight method analyses were closer to the null (HR, 0.67–0.84). Results from the plasmode simulation found that the time-varying exposure, landmark, and clone-censor-weight method models all produced unbiased HRs (bias −0.003 to 0.016). Both standard dichotomous exposure (HR, 0.84; bias, −0.177) and dichotomous with exclusion of immortal time (HR, 0.93; bias, −0.074) produced meaningfully biased estimates. Conclusions: Researchers should use time-varying exposures with a treatment assessment window or the clone-censor-weight method when immortal time is present. Impact: Using methods that appropriately account for immortal time will improve evidence and decision-making from research using real-world data.

Year:

2025

Supplementary Table 2 shows the odds ratios and confidence intervals for associations between contextual factors and adjuvant therapy outcomes for patients with Stage IB grade 3 endometrial cancer.

Year:

2025

Background: Rural patients with endometrial cancer are more likely to receive lower-quality treatment compared with their urban peers. We evaluated the role of contextual factors [rurality, distance to care, and community socioeconomics (SES)] on the receipt of adjuvant therapy (AT): vaginal brachytherapy (VBT), external beam radiation, and chemotherapy. Methods: We analyzed Surveillance Epidemiology and End Results–Medicare and included stages IB grade 3 and stages II to IV. We used county-level rural–urban continuum codes to define rurality, the Yost index to measure community SES, and measure of average driving time to gynecologic oncology care. Multivariable logistic regression was used to estimate adjusted ORs (aOR) and 95% confidence intervals (CI) evaluating AT receipt, adjusting for patient-level clinical and demographic characteristics. Results: A total of 7,572 individuals met inclusion criteria; 15% were rural residing. Rurality was only associated with lower odds of any AT receipt among patients with stage IB endometrial cancer (aOR = 0.62; 95% CI, 0.46–0.83). Increasing travel time was associated with lower odds of VBT (aOR = 0.89; 95% CI, 0.84–0.95). Residence in a low-SES neighborhood was associated with lower odds of chemotherapy (aOR = 0.79; 95% CI, 0.67–0.92) and VBT (aOR = 0.81; 95% CI, 0.69–0.95); however, associations were no longer significant after adjusting for individual SES. Conclusions: Travel time to gynecologic oncology care negatively affects the receipt of treatment regardless of rural or urban residence. Travel time may be a proxy for access to brachytherapy services and may explain the associations between travel and receipt of VBT. Impact: Factors characterizing the place of residence beyond rural/urban residence are important for predicting inequitable access to AT.

Year:

2025

Background Limited research has evaluated the validity of claims‐based definitions for deprescribing. Objectives Evaluate the validity of claims‐based definitions of deprescribing against electronic health records (EHRs) for deprescribing of benzodiazepines (BZDs) after a fall‐related hospitalization. Methods We used a novel data linkage between Medicare fee‐for‐service (FFS) and Part D with our health system's EHR. We identified patients aged ≥66 years with a fall‐related hospitalization, continuous enrollment in Medicare FFS and Part D for 6 months pre‐ and post‐hospitalization, and ≥2 BZD fills in the 6 months pre‐hospitalization. Using a standardized EHR abstraction tool, we adjudicated deprescribing for a sub‐sample with a fall‐related hospitalization at UNC. We evaluated the validity of claims‐based deprescribing definitions (e.g., gaps in supply, dosage reductions) versus chart review using sensitivity and specificity. Results Among 257 patients in the overall sample, 44% were aged 66–74 years, 35% had Medicare low‐income subsidy, 79% were female. Among claims‐based definitions using gaps in supply, the prevalence of BZD deprescribing ranged from 8.2% (no refills) to 36.6% (30‐day gap). When incorporating dosage, the prevalence ranged from 55.3% to 65.8%. Among the validation sub‐sample ( n = 47), approximately one‐third had BZDs deprescribed in the EHR. Compared to EHR, gaps in supply from claims had good sensitivity, but poor specificity. Incorporating dosage increased sensitivity, but worsened specificity. Conclusions The sensitivity of claims‐based definitions for deprescribing of BZDs was low; however, the specificity of a 90‐day gap was >90%. Replication in other EHRs and for other low‐value medications is needed to guide future deprescribing research.

Year:

2024

Purpose The oncology quality, characterization, and assessment of real‐world data (Oncology QCARD) Initiative was formed to develop a set of minimum study design and data elements needed to evaluate the fitness of the real‐world data (RWD) source(s) proposed in an initial study concept as part of early interaction with scientific reviewers. Methods A multidisciplinary executive committee (EC) was established to guide the Oncology QCARD Initiative. The EC conducted a landscape review of published literature, guidances, and guidelines to evaluate relevant dimensions of data quality measurement. Guided by the review and informed by expert feedback, the Oncology QCARD Initial Protocol Characterization (IPC) provides a summary of minimum elements needed to adequately describe an initial clinical study concept that involves RWD and is intended to support decision‐making. Results Fit‐for‐use data and fit‐for‐purpose design emerged as themes from the landscape analysis. Data that are fit‐for‐use are both relevant (sufficiently capturing exposure, outcomes, and covariates) and reliable (understanding data accrual and quality control and whether the data represent the underlying concepts they are intended to represent) to answer a specific research question. A fit‐for‐purpose design takes appropriate steps to ensure internal and external validity and allows for transparency in reporting. The QCARD‐IPC focuses on high‐level characteristics of RWD sources and study design domains including data temporality, population, medical product exposure, comparators, and covariates, endpoints, statistical analysis, and data quality assurance plans. Conclusions Evaluation of studies including RWD requires understanding the data source, study design, and potential biases to preliminarily evaluate whether selected RWD are fit‐for‐use for the research question. The Oncology QCARD‐IPC provides a structured, transparent approach to facilitate early review and enhanced communication between study sponsors and scientific reviewers of initial study proposals including RWD.

Year:

2024

The healthy user effect is a well-recognized bias in the field of pharmacoepidemiology and can be expected to overstate the effect of a preventive intervention when comparing long-term users or “adherers” with nonusers. Similar to the healthy worker effect observed in occupational epidemiology, the healthy user effect can be separated into a healthy initiator effect (baseline confounding) and a healthy adherer effect (selection bias). Restriction approaches and new-user designs that implicitly condition on the indication, and similar healthy behaviors or health status can often mitigate the healthy initiator effect (confounding) or healthy adherer effect (selection bias) at the start of a study. Addressing the healthy adherer effect due to continued conditioning on adherence over the duration of a study is more challenging because methods to mitigate it require the ability to predict adherence, which is often difficult using databases common in pharmacoepidemiologic research. Here, we describe the healthy user effect, with supporting examples, and describe study design approaches available to pharmacoepidemiologists to mitigate the potential for bias. This article is part of a Special Collection on Pharmacoepidemiology.

Year:

2024

Supplementary Table 13 includes the two-year cumulative incidences for HCC surveillance overall and by insurance type, by calendar year of cirrhosis diagnosis, excluding individuals with decompensated cirrhosis (% and 95% confidence intervals).

Year:

2024

Supplementary Table 17 includes two-year cumulative incidences by cirrhosis etiology and by insurance, without imputing deaths for individuals insured through private insurance (% and 95% confidence intervals) (% and 95% confidence intervals).

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (19)

Laura Hanson

University of North Carolina

UNITED STATES
View details

Alexander P. Keil

University of North Carolina

UNITED STATES
View details

Alfred Barritt

University of North Carolina

UNITED STATES
View details

Louise Henderson

Professor

University of North Carolina

UNITED STATES
View details

Paul Duberstein

Senior Associate Dean for Research

Rutgers University

UNITED STATES
View details

Shirley Wang

Brigham and Women's Hospital and Harvard Medical School

UNITED STATES
View details

Victoria Bae-Jump

Professor and Associate Division Director

University of North Carolina at Chapel Hill

UNITED STATES
View details

Katherine Reeder-Hayes

Professor with Tenure

University of North Carolina at Chapel Hill

UNITED STATES
View details

Blánaid Hicks

-

UNITED KINGDOM
View details

Paula D. Strassle

Assistant Professor

University of Maryland at College Park

UNITED STATES
View details

Andrew Olshan

University of North Carolina at Chapel Hill

UNITED STATES
View details

Andrew M. Moon

Assistant Professor

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES
View details

Chris Baggett

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Benjamin Albright

Assistant Professor

University of North Carolina

UNITED STATES
View details

Stephanie B. Wheeler

University of North Carolina at Chapel Hill

UNITED STATES
View details

Hazel B Nichols

Professor

University of North Carolina at Chapel Hill Gillings School of Global Public Health

UNITED STATES
View details

Jihye Park

GlaxoSmithKline (United States)

UNITED STATES
View details

Emilie D. Duchesneau

Assistant Professor

Wake Forest School of Medicine

UNITED STATES
View details

Til Stürmer

Nancy A. Dreyer Distinguished Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details